Breaking News

Avadel Pharma Restructures

Workforce will be downsized by more than 50% to focus resources on FT218 clinical program

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Avadel Pharmaceuticals plc is restructuring to assure funds required to focus on its FT218 clinical program, currently in Phase III development for the treatment of excessive daytime sleepiness (EDS) and Cataplexy in patients suffering from Narcolepsy. Avadel expects to reduce costs by $70 to $75 million in 2019 as a result of the restructuring plan, driven primarily by exiting Noctiva, a treatment for nocturia due to nocturnal polyuria in adults who awaken at least twice per night. Sales of ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters